Brunner Investment Trust (The) — Managing well through choppy waters

The Brunner Investment Trust (LSE: BUT)

Last close As at 04/03/2024

GBP11.80

10.00 (0.85%)

Market capitalisation

500m

More on this equity

Research: Investment Companies

Brunner Investment Trust (The) — Managing well through choppy waters

The Brunner Investment Trust’s (BUT’s) lead manager is Matthew Tillett at Allianz Global Investors. He is ‘delighted’ by the fund’s relative performance so far in 2022, given elevated levels of share price volatility, and points to the balanced investment approach whereby the portfolio is not overexposed to a single factor within the global stock market. He has taken advantage of this volatility to improve the growth profile of BUT’s portfolio as he has been able to invest in some high-quality companies whose valuations would normally be considered prohibitive for the fund, including US software developer Adobe. BUT’s board has just announced the FY22 first interim dividend, which is 9.6% higher year-on-year despite the challenging market backdrop, and it highlighted the trust’s healthy revenue reserves and portfolio income that is comfortably above pre-pandemic levels.

Melanie Jenner

Written by

Mel Jenner

Director, Investment Trusts

flag

Investment Companies

The Brunner Investment Trust

Managing well through choppy waters

Investment trusts
Global equities

14 June 2022

Price

975.0p

Market cap

£416m

AUM

£481m

NAV*

1,107.2p

Discount to NAV

11.9%

*Including income. As at 10 June 2022.

Yield

2.1%

Shares in issue

42.7m

Code

BUT

Primary exchange

LSE

AIC sector

Global

52-week high/low

1,130.0p

942.0p

1,229.0p

1,058.3p

*Including income.

Gearing

Net gearing*

7.1%

*As at 30 April 2022.

Fund objective

The Brunner Investment Trust aims to provide growth in capital value and dividends over the long term through investing in a portfolio of global equities. Its benchmark is a composite of 70% All-World ex-UK (£) Index and 30% All-Share Index.

Bull points

Balanced portfolio of global equities, aiming to generate both capital and income growth.

Long-term record of outperformance versus its benchmark and 50 consecutive years of higher dividends.

Scope for a higher valuation.

Bear points

The fund is likely to underperform in a market led by very high growth or deep value stocks.

Structural gearing of £25m will amplify capital losses in a market sell-off.

Dividend is modestly below the peer group average.

Analyst

Mel Jenner

+44 (0)20 3077 5700

The Brunner Investment Trust is a research client of Edison Investment Research Limited

The Brunner Investment Trust’s (BUT’s) lead manager is Matthew Tillett at Allianz Global Investors. He is ‘delighted’ by the fund’s relative performance so far in 2022, given elevated levels of share price volatility, and points to the balanced investment approach whereby the portfolio is not overexposed to a single factor within the global stock market. He has taken advantage of this volatility to improve the growth profile of BUT’s portfolio as he has been able to invest in some high-quality companies whose valuations would normally be considered prohibitive for the fund, including US software developer Adobe. BUT’s board has just announced the FY22 first interim dividend, which is 9.6% higher year-on-year despite the challenging market backdrop, and it highlighted the trust’s healthy revenue reserves and portfolio income that is comfortably above pre-pandemic levels.

NAV outperformance versus the benchmark over the last three years (Tillett became lead manager on 13 May 2020)

Source: Refinitiv, Edison Investment Research. Note: Total returns in sterling.

The analyst’s view

Tillett’s measured approach and BUT’s diversified portfolio has served investors relatively well during a period of above-average stock market volatility in 2022. The trust offers an active but balanced portfolio of c 65 high-quality global equities across the market cap spectrum, with the prospects of both income and capital growth; BUT has grown its annual dividend in each of the last 50 consecutive years. All stocks are selected on a bottom-up basis and the resulting portfolio currently has meaningful overweight exposures versus the benchmark in industrial and healthcare stocks. The trust’s relative performance has improved since the change of lead manager in May 2020 and BUT’s NAV is ahead of its benchmark over the last one, three, five and 10 years.

Potential for a narrower discount

BUT is currently trading at an 11.9% discount to cum income NAV, which is wider than the 10.0%, 10.4% and 10.4% average discounts over the last one, three and five years respectively. There is scope for a higher valuation given the trust’s commendable relative performance; its NAV total returns rank second over one year and fourth over three years out of the 17 funds in the AIC Global sector.

Recent development

On 9 June 2022, BUT’s board declared the first interim dividend in respect of FY22 at 5.15p per share, which was a 9.6% increase year-on-year. It anticipates a similar level for the second and third interim payments with an unchanged final dividend of 6.05p per share. The total FY22 distribution of 21.50p per share would equate to a 6.7% increase year-on-year and would be the 51st consecutive year of higher annual dividends.

BUT’s board notes that it is impossible to judge the impact that higher interest rates will have on economic growth, but takes comfort from the fact that the manager’s revenue forecasts are comfortably above pre-pandemic levels and the trust has revenue reserves of 24.7p per share, which is 1.15x the anticipated FY22 dividend payment. Based on its current share price, BUT offers a 2.1% yield.

Exhibit 1: Dividend history since FY16

Source: Bloomberg, Edison Investment Research

The fund manager: Matthew Tillett

The manager’s view: Opportunities from market weakness

Commenting on the investment backdrop, Tillett says it has been a difficult start to 2022. Stocks have repriced in an environment of rising interest rates, due to higher inflation expectations. At the end of 2021, certain parts of the market were highly valued, such as technology stocks; these companies have subsequently derated as interest rate expectations have risen and there has been a rotation in investor preference from growth to value stocks. However, cyclical stocks have been more of a concern for investors since the start of the war in Ukraine as there are higher prospects of a hit to consumer confidence with people already facing unprecedented cost increases: this could put consumer discretionary stocks under further pressure. Unsurprisingly, defensive stocks have performed relatively better this year along with those that are short-term beneficiaries of higher inflation, such as energy and mining stocks.

The manager’s opinion is that ‘the changing macroeconomic environment does not warrant a major shift in BUT’s portfolio construction’. He believes that consumers are not financially stretched, as their personal balance sheets were generally in good shape prior to the pandemic and there have not been the excesses that were in evidence before the global financial crisis. Also, unlike then, the financial sector is not distressed, and banks are now well capitalised. Tillett suggests that ‘with the help of pandemic handouts consumers can cope with a certain level of inflation’. Nevertheless, there are signs of a tougher economic environment with major US retailers Target and Walmart both reporting earnings that lagged consensus expectations, due to higher costs. However, despite some companies starting to see some weakening demand, the manager does not feel that there are huge excesses that will lead to an economic collapse.

‘Companies remain investible’, according to the manager and he is taking advantage of share price opportunities when they arise. He considers that inflation is the most important economic variable as it is driving central banks’ monetary policy. They need to raise interest rates to avoid losing their credibility, but in general, they have been slow to react to higher inflation, which they initially viewed as transitory. The US economy was ‘running hot’ says Tillett and there have been widespread supply-side bottlenecks and issues related to China’s COVID-19 lockdowns. However, he believes these pressures should ease and generally, ‘capitalist economies are good at working through supply-side challenges’. Providing more information about China, the manager says there is a political issue to overcome, as President Xi Jinping has staked his reputation on his zero-COVID policy. There is a Chinese party congress in autumn 2022, so Tillett considers that a dramatic change in policy is unlikely until Xi Jinping has established his next term in office. The manager opines that the zero-COVID policy is clearly not working and needs to change towards an improved treatments and more vaccinations approach. He suggests that if demand declines in the West due to the rising cost of living, this could reduce inflationary pressures. In his view, US inflation does not need to go back to 2%, and if the rate of change moderates, that should be sufficient to lead to improved levels of consumer and business confidence. However, he suggests that the timing of any improvement in the inflationary backdrop is uncertain, while the war in Ukraine brings an elevated risk that prices will continue to rise.

While the manager is taking advantage of market weakness, he admits that ‘you can never be sure that all the bad news is baked into stock prices’, although he suggests that the valuations of most cyclical stocks are ‘implying a significant reduction in earnings’. Tillett expects some pressure in the consumer discretionary sector even though so far, earnings reports have ‘generally been okay’. He says that there are companies that have fully recovered and are operating at levels above those experienced in 2019. However, Tillett prefers to focus on those firms that are operating below their 2019 levels, such as travel and leisure stocks, and those with a meaningful Chinese exposure. He believes that for these businesses ‘the post-pandemic rebound will be powerful, and should help to offset any economic weakness’.

Current portfolio positioning

Looking at BUT’s top 10 holdings, at both the end the end of April 2022 and a year earlier, they made up 30.6% of the portfolio; six positions were common to both periods.

Exhibit 2: Top 10 holdings (as at 30 April 2022)

Company

Country

Sector

Portfolio weight %

30 April 2022

30 April 2021*

Microsoft

US

Software & computer services

4.9

4.5

UnitedHealth

US

Healthcare equipment & services

4.8

4.0

Visa

US

Financial services

3.6

2.7

Adidas

Germany

Sportswear manufacturer

2.9

N/A

Roche

Switzerland

Pharmaceuticals & biotechnology

2.8

2.6

Taiwan Semiconductor

Taiwan

Technology hardware & equipment

2.5

2.9

Munich Re

Germany

Non-life insurance

2.4

2.6

Novo Nordisk

Denmark

Pharmaceuticals & biotechnology

2.3

N/A

Shell

UK

Oil & gas producers

2.2

N/A

Schneider Electric

France

Energy management & automation

2.2

N/A

Top 10 (% of portfolio)

30.6

30.6

Source: The Brunner Investment Trust, Edison Investment Research. Note *N/A where not in end-April 2021 top 10.

Over the 12 months to end-April 2022, the largest changes on a geographic basis were a 4.1pp higher UK weighting and a 2.6pp reduction to the trust’s North American exposure. The largest active weights were an overweight allocation to continental Europe and lower weightings to the UK (-6.1pp) and Pacific ex-Japan (-5.4pp).

Exhibit 3: Portfolio geographic exposure versus benchmark (% unless stated)

Portfolio end-
April 2022

Portfolio end-
April 2021

Change
(pp)

Benchmark
weight

Active weight
vs b’mark (pp)

Trust weight/
b’mark weight (x)

North America

43.7

46.3

(2.6)

45.3

(1.6)

1.0

Europe ex-UK

25.6

26.7

(1.1)

9.0

16.6

2.8

UK

23.9

19.8

4.1

30.0

(6.1)

0.8

Pacific ex-Japan

4.0

4.6

(0.6)

9.4

(5.4)

0.4

Japan

2.8

2.7

0.1

4.4

(1.6)

0.6

Latin America

0.0

0.0

0.0

0.7

(0.7)

0.0

Middle East & Africa

0.0

0.0

0.0

1.2

(1.2)

0.0

100.0

100.0

100.0

Source: The Brunner Investment Trust, Edison Investment Research. Note: Excludes cash. Numbers subject to rounding.

A year-on-year comparison is unavailable for BUT’s sector weightings due to changes in sector classifications during the last 12 months. The largest active exposures versus the benchmark are overweight positions in industrials (+7.6pp) and healthcare (+7.0pp) and an underweight to the consumer staples sector (-5.6pp).

Exhibit 4: Portfolio sector exposure versus benchmark (% unless stated)

Portfolio end-
April 2022

Benchmark
weight

Active weight
vs benchmark (pp)

Trust weight/
benchmark weight (x)

Industrials

20.3

12.7

7.6

1.6

Financials

19.0

16.6

2.4

1.1

Healthcare

18.7

11.7

7.0

1.6

Technology

13.7

16.3

(2.6)

0.8

Consumer discretionary

13.3

13.0

0.3

1.0

Energy

4.1

6.0

(1.9)

0.7

Basic materials

3.5

5.4

(1.9)

0.7

Consumer staples

3.3

8.9

(5.6)

0.4

Utilities

3.1

3.3

(0.2)

0.9

Real estate

1.0

3.1

(2.1)

0.3

100.0

100.0

Source: The Brunner Investment Trust, Edison Investment Research. Note: Excludes cash. Numbers subject to rounding.

In April 2022, Tillett added a new position in mid-cap (c £500m) Atalaya Mining to BUT’s portfolio; he says that this company plays into the energy transition theme. Atalaya is a copper miner with assets in Spain on the Pyrite mining belt. The manager considers it to be a very well managed company with an established operational facility, which is generating around 55k tons of copper each year. This commodity is a beneficiary of the electrification of economies and the energy transition away from fossil fuels and is used in products including electric vehicles, solar panels and batteries.

Tillett says that within the copper mining industry the supply side is relatively tight with additional resources located in tough geographical or political areas and suggests that it will be difficult to fulfil the anticipated demand growth over the next 10–20 years. The manager finds Atalaya’s prospects more attractive than those of a large miner with major development projects, helped by Atalaya’s management team’s knowledge around geology, reserves and the company’s growth potential. Atalaya has other higher-grade deposits that are yet to be developed and Tillett believes that this growth potential is underappreciated by the market, where analysts are only modelling the current mine plan. The manager explains that Proyecto Riotinto, its current operating mine, has an 11-year life with its existing deposit, but production and mine life can be grown significantly once the other deposits are brought on line. Atalaya also has blended production capabilities that can respond to current market conditions; if commodity prices are high, it uses lower-grade ore, while if prices are weak, it can shift production to higher-grade ore. Tillett expects the company’s share price to re-rate as investors comes to appreciate its long-term cash flow potential.

The manager explains that Atalaya is listed on AIM and is not a well known company. It had a concentrated share register with three holders each owning around 20%. One sold its position around 12 months ago and then in April 2022, a second holder was a forced seller as it was under financial pressure. As a result, BUT’s position was initiated at a double-digit discount to the prevailing share price. Tillett says the company is expected to move to a main-market listing in the next 12 months, which should make it more visible to investors.

Commenting on other portfolio activity, the manager says that he has been taking some profits in the healthcare sector, such as reducing the position in AbbVie. Following the acquisition of Allergan, the company is less reliant on Humira for the treatment of autoimmune conditions. However, Humira still represented 37% of AbbVie’s 2021 revenues and is going off patent next year. Tillett believes that the company is ‘likely to struggle to grow’ its earnings over the next two to three years. The manager has also been adding to some high-quality industrial companies in the fund such as Assa Abloy and Atlas Copco, which he considers to be moderately cyclical businesses with positive structural drivers that are now trading at attractive valuations.

A few months ago, the manager added to BUT’s Adidas position. This stock has performed poorly, which Tillett believes is due to its meaningful exposure to China, where its business is very depressed. He suggests that any normalisation of the Chinese economy over the next 12–18 months should be beneficial for Adidas. The manager believes that the post-pandemic kicker is underappreciated and should benefit some of BUT’s other holdings, including Booking Holdings, Bright Horizons Family Solutions, Estée Lauder Companies and Yum! Brands. In February 2022, Tillett sold BUT’s positions in Fresenius and Merlin Properties, as Tillett identified better opportunities elsewhere in the fund.

The manager highlights the trust’s position in Homeserve, citing it as a good example of a smaller cap, good-quality company with a defensive repeatable business. Its UK operations have been weak, but North America is now its largest market and is growing at 10–15% pa; Tillett suggests that this business alone could justify the valuation of the whole company. He added Homeserve to BUT’s portfolio in late 2021 and its board has recently recommended a £12 per share takeover bid from Canada-based Brookfield Asset Management. This is a 95% premium to Homeserve’s year-to-date low share price point in early February 2022.

Performance: Navigating a volatile stock market

Exhibit 5: Five-year discrete performance data

12 months ending

Share price
(%)

NAV*
(%)

Benchmark**
(%)

CBOE UK All Companies (%)

MSCI All World exUK (%)

31/05/18

15.7

10.1

8.6

6.6

9.3

31/05/19

(0.1)

1.5

2.7

(3.4)

5.2

31/05/20

3.2

3.7

2.7

(12.0)

9.2

31/05/21

29.6

27.1

24.2

23.4

24.1

31/05/22

4.0

7.7

6.5

8.5

5.2

Source: Refinitiv. Note: All % on a total return basis in pounds sterling. *NAV with debt at market value.

Exhibit 6: Share price and NAV total return performance, relative to indices (%)

 

One month

Three months

Six months

One year

Three years

Five years

10 years

Price relative to benchmark

(2.0)

(4.0)

(2.2)

(2.3)

2.4

6.2

13.4

NAV relative to benchmark

0.8

1.2

1.1

1.1

4.5

4.7

10.7

Price relative to CBOE UK All Companies

(2.7)

(5.4)

(9.9)

(4.1)

18.1

32.7

55.5

NAV relative to CBOE UK All Companies

0.0

(0.2)

(6.8)

(0.7)

20.6

30.8

51.9

Price relative to MSCI All World ex-UK

(1.7)

(3.3)

1.6

(1.2)

(2.5)

(1.9)

(3.9)

NAV relative to MSCI All World ex-UK

1.1

1.9

5.0

2.3

(0.5)

(3.3)

(6.1)

Source: Refinitiv, Edison Investment Research. Note: Data to end-May 2022. Geometric calculation.

Exhibit 6 shows BUT’s relative performance, its NAV is ahead of the benchmark over all periods shown, while its share price has outperformed over the last three, five and 10 years. There is also a notable outperformance versus the broad UK market over the last three, five and 10 years, illustrating the potential benefits of considering stocks that are listed overseas. Tillett is very encouraged by BUT’s performance in a tricky market. He highlights that in the 12 months to end-April 2022, the top four best active contributors to the trust’s performance were all healthcare stocks: UnitedHealth Group (+117bp); Novo Nordisk (+102bp); AbbVie (+80bp) and Roche Holdings (+51bp). On the negative side the three worst active contributors were Adidas (-105bp) and not holding Apple (-65bp) and AstraZeneca (-52bp).

Exhibit 7: Investment trust performance to 31 May 2022

Price, NAV and benchmark total return performance, one-year rebased

Price, NAV and benchmark total return performance (%)

Source: Refinitiv, Edison Investment Research. Note: Three-, five- and 10-year performance figures annualised.

Exhibit 8: NAV performance versus benchmark over five years

Source: Refinitiv, Edison Investment Research

Peer group comparison

There are 17 funds in the AIC Global sector, with the peers following a variety of investment mandates. BUT can be categorised as one of the ‘core’ funds in the group given its balanced approach of aiming to generate both capital and income growth, straightforward equity portfolio and no exposure to unlisted companies. The trust’s relative performance continues to improve with its NAV total returns now ranking a very creditable second over the past 12 months, fourth over the last three years, seventh over five years and ninth (out of 16 funds) over the last decade. BUT’s returns are above the peer group averages over the last one, three and five years.

There has been relatively weak performance over the last year at some of BUT’s peers with a growth mandate such as Manchester and London Investment Trust, Monks Investment Trust and Scottish Mortgage Investment Trust, which highlights the different approaches within the peer group, that can lead to different results. BUT’s proposition is a more stable, ‘all-weather fund’ that aims to add value across varied market cycles. The manager has a flexible, ‘lower-risk’ approach and the backing of a well-resourced investment team, and some investors favour BUT’s high-conviction, more concentrated portfolio rather than those of its more diversified ‘core’ peers such as Bankers Investment Trust, F&C Investment Trust and Witan Investment Trust.

BUT’s discount is currently wider than the peer-group average, which one may consider surprising given the trust’s improving performance record and balanced investment approach. It has a competitive ongoing charge and a below-average level of gearing. BUT’s 2.1% dividend yield is 30bp lower than the sector average.

Exhibit 9: AIC Global sector at 10 June 2022*

% unless stated

Market
cap £m

NAV TR
1 year

NAV TR
3 year

NAV TR
5 year

NAV TR
10 year

Discount
(cum-fair)

Ongoing charge

Perf.
fee

Net gearing

Dividend yield

Brunner Investment Trust

423.1

2.8

33.4

47.6

187.1

(10.6)

0.6

No

107

2.1

Alliance Trust

2,818.2

(2.1)

30.4

45.8

198.2

(5.1)

0.6

No

106

2.5

AVI Global Trust

938.2

0.8

35.8

49.4

184.9

(11.1)

0.8

No

100

1.8

Bankers Investment Trust

1,309.8

(2.8)

26.0

44.0

209.4

(6.8)

0.5

No

108

2.2

Blue Planet Investment Trust

6.2

(57.9)

(66.1)

(66.5)

(6.9)

4.3

No

146

4.2

F&C Investment Trust

4,216.3

1.1

33.4

51.8

224.9

(11.2)

0.5

No

107

1.6

Global Opportunities Trust

84.2

11.4

16.9

18.0

150.7

(16.2)

1.0

No

100

1.7

JPMorgan Elect Managed Growth

260.8

(4.5)

24.4

40.4

202.7

(1.4)

0.5

No

100

1.8

Keystone Positive Change Inv

120.0

(27.1)

(35.3)

(36.7)

21.3

(10.4)

0.5

No

111

5.8

Lindsell Train Investment Trust

218.0

(11.8)

15.2

83.7

459.3

3.0

0.8

Yes

100

4.6

Manchester & London Inv Trust

147.4

(24.8)

1.0

25.2

92.6

(21.0)

0.8

Yes

100

3.8

Martin Currie Global Portfolio

256.2

(15.8)

17.2

42.3

182.5

(2.1)

0.7

No

111

1.4

Mid Wynd International Inv Trust

476.6

(1.6)

38.6

67.7

254.2

2.2

0.6

No

100

1.0

Monks Investment Trust

2,122.0

(21.4)

23.5

48.8

198.2

(9.6)

0.4

No

108

0.2

Scottish Investment Trust

547.9

1.7

8.5

10.5

116.2

(3.5)

0.6

No

102

3.1

Scottish Mortgage Inv Trust

10,753.9

(33.3)

72.4

116.3

532.6

(11.9)

0.3

No

117

0.5

Witan Investment Trust

1,505.0

(7.7)

16.6

24.9

185.5

(9.5)

0.7

Yes

113

2.7

Average (17 funds)

1,541.4

(11.4)

17.2

36.1

212.5

(7.8)

0.8

108

2.4

BUT rank in sector

10

2

4

7

9

12

10

8

9

Source: Morningstar, Edison Investment Research. Note: *Performance to 9 June 2022 based on ex-par NAV. TR = total return. Net gearing is total assets less cash and equivalents as a percentage of net assets.

General disclaimer and copyright

This report has been commissioned by The Brunner Investment Trust and prepared and issued by Edison, in consideration of a fee payable by The Brunner Investment Trust. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright: Copyright 2022 Edison Investment Research Limited (Edison).

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

1185 Avenue of the Americas

3rd Floor, New York, NY 10036

United States of America

Sydney +61 (0)2 8249 8342

Level 4, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

1185 Avenue of the Americas

3rd Floor, New York, NY 10036

United States of America

Sydney +61 (0)2 8249 8342

Level 4, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

General disclaimer and copyright

This report has been commissioned by The Brunner Investment Trust and prepared and issued by Edison, in consideration of a fee payable by The Brunner Investment Trust. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright: Copyright 2022 Edison Investment Research Limited (Edison).

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

1185 Avenue of the Americas

3rd Floor, New York, NY 10036

United States of America

Sydney +61 (0)2 8249 8342

Level 4, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

1185 Avenue of the Americas

3rd Floor, New York, NY 10036

United States of America

Sydney +61 (0)2 8249 8342

Level 4, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

More on The Brunner Investment Trust

View All

Latest from the Investment Companies sector

View All Investment Companies content

Research: Healthcare

IRLAB Therapeutics — Richard Godfrey appointed as new CEO

IRLAB Therapeutics has announced the appointment of Richard Godfrey as its new CEO, replacing Nicholas Waters. The new management structure will see Richard Godfrey focus on IRLAB’s commercial development, while Nicholas Waters (an IRLAB founder) will become vice president and head of R&D. He will lead further evolution of the company’s clinical assets and R&D platform. In our view, the move strengthens IRLAB’s management team and will allow the company to better focus on developing its main central nervous system assets, mesdopetam and pirepemat, along with its burgeoning preclinical pipeline and the Integrative Screening Process (ISP). Our estimates are under review.

Continue Reading
flag

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free